China

ViiV Healthcare's Positive Action on HIV/AIDS

Set up in 1992, Positive Action is ViiV Healthcare's international HIV/AIDS education, care and community support program. It works with community organizations to build capacity to counter the ignorance and stigma surrounding HIV and AIDS through outreach, education and advocacy. In 2009, ViiV Healthcare provided more than GBP 1 million, funding projects in 46 countries across Africa, Asia, Latin America and Eastern Europe.

Staying Away from Tobacco for a Healthy Life

China, with approximately 350 million smokers, produces and consumes more cigarettes than any other country in the world. Pfizer China anticipated its parent company's global tobacco control initiative (see Global Health Partnerships) by supporting the Chinese government's efforts to promote smoking cessation through a series of community awareness and education programs, notably a three-year smoking cessation initiative by the Beijing University Medical School called 'Staying Away from Tobacco for a Healthy Life'.

Pfizer Global Health Partnerships

Pfizer has a responsibility to direct its resources and expertise to address the world's most enduring health challenges. Cancer is one of these challenges and Pfizer recognizes that only by working together with those who share a vision of a healthier world can we make a significant impact toward eradicating this disease that has outlived too many generations. Pfizer's Global Health Partnerships (GHP) Program is one approach it is taking to tackle the global cancer epidemic.

Pfizer Global Health Fellows

The Pfizer Global Health Fellows program utilizes the professional expertise of Pfizer employees through specialized volunteer assignments with nonprofit organizations to improve health care services for underserved communities around the world. Since 2003, more than 230 employees with a range of technical skills have served in 39 nations for 3-6 month assignments investing nearly 200,000 hours of skills-based service to help increase the capacity of nonprofits organizations providing health care to the underserved (in the reporting period, 54 Global Health Fellows were deployed).

Pandemic Influenza & Developing Countries

Social factors make poor countries particularly vulnerable to an influenza pandemic and they are less able to afford vaccines and antiviral medicines. GlaxoSmithKline (GSK) has invested over USD 2 billion in research and expanded production capacity for its antiviral medicine, Relenza, and for its pre-pandemic and pandemic influenza vaccines. It has set a preferential price for Relenza for Least-Developed Countries (LDCs) and has granted Simcere, China, a voluntary licence to make zanamivir and sell it in China, Indonesia, Thailand, Vietnam and all LDCs.

Otsuka Pharmaceutical: MDR-Tuberculosis R&D

At a preclinical level, Otsuka Pharmaceutical's OPC-67683 has shown particularly strong bactericidal activity on Mycobacterium tuberculosis. The compound has also been confirmed to have no cross resistance with any of the currently used anti-tuberculosis agents and its strong bactericidal effect is seen even on clinically isolated strains of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB).

Novo Nordisk: World Partner Project

The diabetes pandemic will undoubtedly affect developing countries' ability to grow and develop. The World Partner Project (WPP) was launched in 2001 to establish a foundation on which developing countries can build their own diabetes healthcare strategies and ultimately improve access to proper care. The WPP works with local partners, usually health ministries and/or patient organizations, and is funded by a grant from Novo Nordisk.

Novo Nordisk: Haemophilia Foundation

The Novo Nordisk Haemophilia Foundation (NNHF) was created in 2005 to address the significant need to improve haemophilia treatment in developing countries, where it is not a healthcare priority and many patients go undiagnosed or are inadequately treated. Consequently, life expectancy for people with haemophilia is low and treatment with clotting factors is suboptimal. NNHF is an independent trust, located in Zurich, Switzerland, and funds programs to improve hemophilia care, treatment and awareness in the developing world.

Merck & Co., Inc. HIV/AIDS Programs - China

In 2005, Merck & Co., Inc. and the Government of China established the first large-scale comprehensive public/private partnership known as the China-MSD HIV/AIDS Partnership (C-MAP), to address HIV and AIDS prevention, patient care, treatment and support, in support of "China's Action Plan for Reducing & Preventing the spread of HIV/AIDS 2006-2010." The partners introduced the program in Liangshan Prefecture, Sichuan Province, with the aim of developing a model that could be replicated in other provinces.

Lilly MDR-TB Partnership

The Lilly MDR-TB Partnership involves transferring Lilly's proprietary manufacturing technology to partner companies.

Pages